Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Charleston
mi
from
Charleston, SC
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
CCOP - Greenville
mi
from
Greenville, SC
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Erlanger Cancer Center
mi
from
Chattanooga, TN
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Erlanger Cancer Center
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
mi
from
Nashville, TN
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Amarillo
mi
from
Amarillo, TX
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Cottonwood Hospital Medical Center
mi
from
Murray, UT
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Cottonwood Hospital Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
McKay-Dee Hospital Center
mi
from
Ogden, UT
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
McKay-Dee Hospital Center
mi
from
Ogden, UT
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Utah Valley Regional Medical Center - Provo
mi
from
Provo, UT
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Utah Valley Regional Medical Center - Provo
mi
from
Provo, UT
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Dixie Regional Medical Center
mi
from
Saint George, UT
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Dixie Regional Medical Center
mi
from
Saint George, UT
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
All Saints Cancer Center at All Saints Healthcare
mi
from
Racine, WI
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
All Saints Cancer Center at All Saints Healthcare
mi
from
Racine, WI
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Westmead Hospital
mi
from
Westmead,
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Westmead Hospital
mi
from
Westmead,
Click here to add this to my saved trials
Metabolism of NNK Among African Americans
Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking: Project 5: Metabolism of NNK Among African Americans
Status: Enrolling
Updated:  3/13/2017
Tobacco Research Programs University of Minnesota
mi
from
Minneapolis, MN
Metabolism of NNK Among African Americans
Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking: Project 5: Metabolism of NNK Among African Americans
Status: Enrolling
Updated: 3/13/2017
Tobacco Research Programs University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Phase I Trial of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Status: Enrolling
Updated:  3/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Phase I Trial of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Status: Enrolling
Updated: 3/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Preventing Sexual Dysfunction With Aromatase Inhibitors
Preventing Sexual Dysfunction in Women on Aromatase Inhibitors
Status: Enrolling
Updated:  3/13/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Preventing Sexual Dysfunction With Aromatase Inhibitors
Preventing Sexual Dysfunction in Women on Aromatase Inhibitors
Status: Enrolling
Updated: 3/13/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors
A Phase I/II Dose-Escalation/Efficacy Study of Palliative Extracranial Radiosurgery Using the Elektra Stereotactic Body Frame System
Status: Enrolling
Updated:  3/13/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors
A Phase I/II Dose-Escalation/Efficacy Study of Palliative Extracranial Radiosurgery Using the Elektra Stereotactic Body Frame System
Status: Enrolling
Updated: 3/13/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Status: Enrolling
Updated:  3/13/2017
Scottsdale Clinical Research Institute
mi
from
Scottsdale, AZ
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Status: Enrolling
Updated: 3/13/2017
Scottsdale Clinical Research Institute
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Status: Enrolling
Updated:  3/13/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Status: Enrolling
Updated: 3/13/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Status: Enrolling
Updated:  3/13/2017
Nevada Cancer Institute
mi
from
Las Vegas, NV
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Status: Enrolling
Updated: 3/13/2017
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
AMPM Research Clinic
mi
from
Miami, FL
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
AMPM Research Clinic
mi
from
Miami, FL
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
Illinois Cancer Care
mi
from
Peoria, IL
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
Commonwealth Hematology-Oncology
mi
from
Lawrence, MA
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
Commonwealth Hematology-Oncology
mi
from
Lawrence, MA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Southern California / Keck Hospital
mi
from
Los Angeles, CA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Southern California / Keck Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Florida Hospital Transplant Institute
mi
from
Orlando, FL
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Florida Hospital Transplant Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Piedmont Hospital
mi
from
Atlanta, GA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Emory University School of Medicine
mi
from
Atlanta, GA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Ochsner Medical Center
mi
from
New Orleans, LA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Lahey Hospital
mi
from
Burlington, MA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Lahey Hospital
mi
from
Burlington, MA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Mount Sinai Hospital
mi
from
New York, NY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Methodist University Hospital
mi
from
Memphis, TN
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Methodist University Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials